Gilead Sciences, Inc. GILD
150.93
1.24
0.83%
as of 25 Sep
- Market cap
- $183.2B
- P/E
- 0.0×
Follow GILD
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
Gilead Sciences, Inc. (GILD) Operating cash flow
Gilead Sciences, Inc.'s operating cash flow for fiscal 2025 was $10.0B, down 7.47% from $10.8B in fiscal 2024. Over the twelve months to 30 June 2026 it was $13.6B. Over the past ten years it has ranged from $8.0B (fiscal 2023) to $21.3B (fiscal 2015); the current reading is higher than 55% of that period. Gilead Sciences, Inc. ranks 9th of 21 Drug Manufacturers General companies by operating cash flow.
Operating cash flow, annual
Annual
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $10.0B | (7.47%) |
| FY2024 | $10.8B | 35.25% |
| FY2023 | $8.0B | (11.75%) |
| FY2022 | $9.1B | (20.31%) |
| FY2021 | $11.4B | 39.37% |
| FY2020 | $8.2B | (10.67%) |
| FY2019 | $9.1B | 8.86% |
| FY2018 | $8.4B | (29.40%) |
| FY2017 | $11.9B | (30.20%) |
| FY2016 | $17.0B | (19.78%) |
Quarterly
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $3.6B | 40.45% |
| Mar 2026 | $2.5B | (23.53%) |
| Dec 2025 | $3.3B | (19.01%) |
| Sep 2025 | $4.1B | 396.74% |
| 42 more quarters | Free account |
Against its own ten years
Low $8.0B
High $21.3B
Ten-year median
$10.0B
Current reading's percentile
55
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| SNY Sanofi compare | $21.6B |
| NVO Novo Nordisk A/S compare | $20.4B |
| NVS Novartis AG compare | $18.4B |
| AZN AstraZeneca PLC compare | $13.7B |
| GILD Gilead Sciences, Inc. | $13.6B |
| PFE Pfizer Inc. compare | $13.4B |
| BMY Bristol Myers Squibb Company compare | $12.8B |
| AMGN Amgen Inc. compare | $12.5B |
| GSK GSK PLC Sponsored ADR compare | $11.0B |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on GILD
- Revenue
- Net income
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement